<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">This review summarizes currently available nucleos(t)ide-based drugs and their acyclic analogues that exhibit multi-target activity against viral infections of great medical importance (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV)) and/or that are known antineoplastic agents used to treat cancer. Approved nucleos(t)ide-based drugs with multi-target activity and compounds being tested in clinical trials or evaluated in preclinical assays are listed in 
 <xref rid="tbl1" ref-type="table">Table 1</xref> . In this paper, the term “approval date” means the date on which the drug was approved by the US Food and Drug Administration (FDA) unless otherwise stated.
</p>
